MPG.eBooks - Search Results - "Multiple Sclerosis, Relapsing-remitting / Drug Therapy"

Search alternatives:
relapsing » relating , relaxing
"Multiple Sclerosis, Relapsing-remitting / Drug Therapy" » "Multiple Sclerosis, Relapsing-emitting / Drug Therapy", "Multiple Sclerosis, Relapsing-permitting / Drug Therapy", "Multiple Sclerosis, Relapsing-admitting / Drug Therapy"

Cover Image

1

Management of relapsing-remitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

2

Management of relapsing-remitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

3

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

4

Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

5

Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

6

Pharmacoeconomic review report: Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (R...

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

7

Pharmacoeconomic review report: Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

8

Clinical review report: Cladribine (Mavenclad) (EMD serono)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

9

Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

10

Medicines used for multiple sclerosis : a health technology assessment

by Couto, Elisabeth
Published 2016

Norwegian Institute for Public Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

11

Pharmacoeconomic review report: Daclizumab (Zinbryta)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

12

Clinical review report: Cladribine (Mavenclad) (EMD serono)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

13

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

14

Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis : project protocol

Published 2012

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

15

Teriflunomide (Aubagio) (14 mg film-coated tablet)

Published 2014

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

16

CADTH Canadian Drug Expert Committee recommendation: Cladribine (Mavenclad -- EMD Serono) : indication: relapsing-remitting multiple sclerosis

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

17

CADTH Canadian Drug Expert Committee recommendation: Daclizumab (Zinbryta -- Biogen Canada Inc.) : indication: relapsing-remitting multiple sclerosis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

18

Recommendations for drug therapies for relapsing-emitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

19

Recommendations for drug therapies for relapsing-emitting multiple sclerosis

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

Cover Image

20

Second-line therapy for patients with relapsing-remitting multiple sclerosis : a review of guidelines

by Li, Ke Xin, Picheca, Lory
Published 2019

CADTH

Subjects: “...Multiple Sclerosis, Relapsing-Remitting / drug therapy...”

1
2